Indivior PLC
LSE:INDV

Watchlist Manager
Indivior PLC Logo
Indivior PLC
LSE:INDV
Watchlist
Price: 932 GBX 1.91%
Market Cap: 1.2B GBX
Have any thoughts about
Indivior PLC?
Write Note

Indivior PLC
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Indivior PLC
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Indivior PLC
LSE:INDV
Total Equity
-$121m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-9%
GlaxoSmithKline PLC
LSE:GSK
Total Equity
ÂŁ14.4B
CAGR 3-Years
-2%
CAGR 5-Years
32%
CAGR 10-Years
9%
AstraZeneca PLC
LSE:AZN
Total Equity
$39.5B
CAGR 3-Years
36%
CAGR 5-Years
24%
CAGR 10-Years
6%
Verona Pharma PLC
NASDAQ:VRNA
Total Equity
$130.5m
CAGR 3-Years
-8%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Total Equity
$2.3B
CAGR 3-Years
0%
CAGR 5-Years
5%
CAGR 10-Years
7%
Dechra Pharmaceuticals PLC
LSE:DPH
Total Equity
ÂŁ755.2m
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
16%
No Stocks Found

Indivior PLC
Glance View

Market Cap
1.2B GBX
Industry
Pharmaceuticals

Indivior PLC, a pivotal player in the pharmaceutical landscape, traces its roots back to a dedicated focus on addiction treatment. With an origin steeped in addressing opioid dependency, the company carved out a significant niche by developing and marketing medication-assisted treatments. At the heart of Indivior's success is its flagship product, Suboxone, which combines buprenorphine and naloxone to manage opioid addiction. This formulation, integral in combating withdrawal symptoms and reducing the allure of opioids, positioned Indivior as an innovator in an era when the opioid crisis commanded urgent attention. The company's revenue model leverages the growing need for comprehensive drug dependence solutions, primarily driven by its robust portfolio of treatment options. By relentlessly advocating for effective healthcare policies and ensuring substantial product availability, Indivior maintains its competitive edge. The company's strategy is not just confined to novel drug development, but also focuses on expanding treatment access globally, aligning profitability with public health imperatives. This dual commitment to innovation and societal impact ensures that Indivior remains a significant force in the healthcare sector, adeptly navigating the complexities of addiction treatment while generating sustainable financial growth.

INDV Intrinsic Value
2 223 GBX
Undervaluation 58%
Intrinsic Value
Price

See Also

What is Indivior PLC's Total Equity?
Total Equity
-121m USD

Based on the financial report for Jun 30, 2024, Indivior PLC's Total Equity amounts to -121m USD.

What is Indivior PLC's Total Equity growth rate?
Total Equity CAGR 10Y
-9%

Back to Top